Operating Expenses
Amortization of Finite-Lived Intangible Assets
Vertex Pharmaceuticals Amortization of Finite-Lived Intangible Assets remained flat by 0.0% to $5.05M in Q4 2025 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $5.05M to $5.05M. Over 2 years (FY 2023 to FY 2025), Amortization of Finite-Lived Intangible Assets shows an upward trend with a 244.7% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
First reportedQ1 2023
Last reportedQ4 2025Feb 13, 2026
Metric ID:
amgn_amortization_of_finite_lived_intangiblesHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $1.70M | $20.20M | $20.20M |
| YoY Change | — | >999% | +0.0% |
Range$1.70M – $20.20M
CAGR+244.7%
Avg YoY Growth+544.1%
Median YoY Growth+544.1%
Current Streak2+ years growth
Amortization of Finite-Lived Intangible Assets at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's amortization of finite-lived intangible assets?
- Vertex Pharmaceuticals (VRTX) reported amortization of finite-lived intangible assets of $5.05M in Q4 2025.
- How has Vertex Pharmaceuticals's amortization of finite-lived intangible assets changed year-over-year?
- Vertex Pharmaceuticals's amortization of finite-lived intangible assets decreased by 0.0% year-over-year, from $5.05M to $5.05M.
- What is the long-term trend for Vertex Pharmaceuticals's amortization of finite-lived intangible assets?
- Over 2 years (2023 to 2025), Vertex Pharmaceuticals's amortization of finite-lived intangible assets has grown at a 244.7% compound annual growth rate (CAGR), from $1.70M to $20.20M.